All doses of Eli Lilly’s weight loss drugs Zepbound and Mounjaro are available in the United States after more than a year of being in shortage, according to the Food and Drug Administration’s ...

Eli Lilly & Co. sent a wave of letters to US healthcare providers in recent days demanding they stop promoting copycat weight-loss drugs as supply of the company’s brand-name medicines improves.

Eli Lilly and Company (NYSE: LLY) announced today that Marschall S. Runge, M.D., Ph.D. is retiring from his role as an independent director of Lilly's board of directors effective Aug. 31, 2024 ...

The ongoing shortage of Eli Lilly's (NYSE:LLY) highly popular weight loss drug, Zepbound, in the U.S., is expected to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Eli Lilly & Co.’s stock was on pace for its worst day in about three years Thursday as investors fretted about intensifying competition among obesity-drug developers. Lilly’s stock LLY was ...

Eli Lilly stock (NYSE: LLY) has seen its stock rise by around 50% this year, outperforming the broader indices, with the S&P 500 up over 15%. The stock now trades at 63x projected 2024 earnings of ...

Mounjaro has become a leading GLP-1 product and could drive years of growth at Eli Lilly. The company has a great product portfolio and pipeline. Excellent investment returns have impacted the ...

On Tuesday, Eli Lilly unveiled a towering 346,000-square-foot laboratory in Boston’s Seaport District, a building that will house 500 of the company’s scientists — 300 of whom are still to ...

Rep. Eli Crane, R-Ariz., discusses the 'stolen valor' allegations against Democratic VP candidate Tim Walz on 'The Ingraham Angle.' ...

On November 25, 2023, Eli Gold delivered his final call as the voice of Alabama. It was one of many instantly iconic Eli Gold calls: a hail mary touchdown pass from Jalen Milore to Isaiah Bond to ...

Eli Lilly and Company (NYSE: LLY) announced today that Marschall S. Runge, M.D., Ph.D. is retiring from his role as an independent director of Lilly's board of directors effective Aug. 31, 2024 ...